Shaji K. Kumar, MD, discusses the results of a phase II trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib.
Clinical Pearls
Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the results of a phase II trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib.
16% of patients had a pre-specified response (minimum minor response by end of Cycle 2 or partial response by end of Cycle 4)
35% of patients had partial response or better under the approach of receiving MLN9708 alone and adding dexamethasone if it did not work well
The most common side effects in this trial (fatigue, drop in platelet counts, nausea, and diarrhea) were well managed
